000257330 001__ 257330
000257330 005__ 20231120155338.0
000257330 0247_ $$2doi$$a10.3390/cells12060957
000257330 0247_ $$2pmid$$apmid:36980297
000257330 0247_ $$2pmc$$apmc:PMC10047140
000257330 0247_ $$2altmetric$$aaltmetric:144286063
000257330 037__ $$aDZNE-2023-00399
000257330 041__ $$aEnglish
000257330 082__ $$a570
000257330 1001_ $$0P:(DE-2719)2812631$$aSchreiber, Stefanie$$b0
000257330 245__ $$aBrain Vascular Health in ALS Is Mediated through Motor Cortex Microvascular Integrity.
000257330 260__ $$aBasel$$bMDPI$$c2023
000257330 3367_ $$2DRIVER$$aarticle
000257330 3367_ $$2DataCite$$aOutput Types/Journal article
000257330 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1680772883_19772$$xReview Article
000257330 3367_ $$2BibTeX$$aARTICLE
000257330 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000257330 3367_ $$00$$2EndNote$$aJournal Article
000257330 500__ $$aCC BY
000257330 520__ $$aBrain vascular health appears to be critical for preventing the development of amyotrophic lateral sclerosis (ALS) and slowing its progression. ALS patients often demonstrate cardiovascular risk factors and commonly suffer from cerebrovascular disease, with evidence of pathological alterations in their small cerebral blood vessels. Impaired vascular brain health has detrimental effects on motor neurons: vascular endothelial growth factor levels are lowered in ALS, which can compromise endothelial cell formation and the integrity of the blood-brain barrier. Increased turnover of neurovascular unit cells precedes their senescence, which, together with pericyte alterations, further fosters the failure of toxic metabolite removal. We here provide a comprehensive overview of the pathogenesis of impaired brain vascular health in ALS and how novel magnetic resonance imaging techniques can aid its detection. In particular, we discuss vascular patterns of blood supply to the motor cortex with the number of branches from the anterior and middle cerebral arteries acting as a novel marker of resistance and resilience against downstream effects of vascular risk and events in ALS. We outline how certain interventions adapted to patient needs and capabilities have the potential to mechanistically target the brain microvasculature towards favorable motor cortex blood supply patterns. Through this strategy, we aim to guide novel approaches to ALS management and a better understanding of ALS pathophysiology.
000257330 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000257330 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000257330 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x2
000257330 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000257330 650_7 $$2Other$$aamyotrophic lateral sclerosis
000257330 650_7 $$2Other$$aexerkines
000257330 650_7 $$2Other$$amotor cortex
000257330 650_7 $$2Other$$apericytes
000257330 650_7 $$2Other$$avascular supply
000257330 650_7 $$2NLM Chemicals$$aVascular Endothelial Growth Factor A
000257330 650_2 $$2MeSH$$aHumans
000257330 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: metabolism
000257330 650_2 $$2MeSH$$aMotor Cortex: metabolism
000257330 650_2 $$2MeSH$$aVascular Endothelial Growth Factor A: metabolism
000257330 650_2 $$2MeSH$$aMotor Neurons: pathology
000257330 650_2 $$2MeSH$$aBlood-Brain Barrier: pathology
000257330 7001_ $$0P:(DE-2719)9001989$$aBernal Moya, Jose$$b1$$udzne
000257330 7001_ $$00000-0002-0517-6473$$aArndt, Philipp$$b2
000257330 7001_ $$0P:(DE-2719)9000986$$aSchreiber, Frank$$b3$$udzne
000257330 7001_ $$0P:(DE-2719)2811487$$aMüller, Patrick$$b4$$udzne
000257330 7001_ $$00000-0002-3957-3848$$aMorton, Lorena$$b5
000257330 7001_ $$aBraun-Dullaeus, Rüdiger Christian$$b6
000257330 7001_ $$00000-0003-2771-6546$$aValdés-Hernández, Maria Del Carmen$$b7
000257330 7001_ $$aDuarte, Roberto$$b8
000257330 7001_ $$00000-0002-9812-6642$$aWardlaw, Joanna Marguerite$$b9
000257330 7001_ $$aMeuth, Sven Günther$$b10
000257330 7001_ $$aMietzner, Grazia$$b11
000257330 7001_ $$0P:(DE-2719)2000035$$aVielhaber, Stefan$$b12$$udzne
000257330 7001_ $$aDunay, Ildiko Rita$$b13
000257330 7001_ $$0P:(DE-2719)2810577$$aDityatev, Alexander$$b14
000257330 7001_ $$0P:(DE-2719)2813348$$aJandke, Solveig$$b15$$udzne
000257330 7001_ $$0P:(DE-2719)9002178$$aMattern, Hendrik$$b16$$eLast author$$udzne
000257330 770__ $$aAmyotrophic Lateral Sclerosis: Understanding the Pathogenetic Mechanisms for the Development of New Therapies
000257330 773__ $$0PERI:(DE-600)2661518-6$$a10.3390/cells12060957$$gVol. 12, no. 6, p. 957 -$$n6$$p957$$tCells$$v12$$x2073-4409$$y2023
000257330 8564_ $$uhttps://pub.dzne.de/record/257330/files/DZNE-2023-00399.pdf$$yOpenAccess
000257330 8564_ $$uhttps://pub.dzne.de/record/257330/files/DZNE-2023-00399.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000257330 909CO $$ooai:pub.dzne.de:257330$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000257330 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812631$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000257330 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001989$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000257330 9101_ $$0I:(DE-588)1065079516$$60000-0002-0517-6473$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000257330 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000986$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000257330 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811487$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000257330 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2000035$$aExternal Institute$$b12$$kExtern
000257330 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810577$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000257330 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2813348$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000257330 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000257330 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000257330 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000257330 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x2
000257330 9141_ $$y2023
000257330 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000257330 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000257330 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000257330 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000257330 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000257330 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000257330 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000257330 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-08-01T15:15:06Z
000257330 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-08-01T15:15:06Z
000257330 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-08-01T15:15:06Z
000257330 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELLS-BASEL : 2022$$d2023-10-26
000257330 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000257330 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000257330 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000257330 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000257330 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000257330 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000257330 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000257330 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000257330 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELLS-BASEL : 2022$$d2023-10-26
000257330 9201_ $$0I:(DE-2719)1310005$$kAG Reymann$$lPathophysiology of Dementia$$x0
000257330 9201_ $$0I:(DE-2719)1310010$$kAG Schreiber$$lMixed Cerebral Pathologies and Cognitive Aging$$x1
000257330 9201_ $$0I:(DE-2719)5000006$$kAG Düzel 3$$lClinical Neurophysiology and Memory$$x2
000257330 9201_ $$0I:(DE-2719)1310003$$kAG Müller$$lNeuroprotection$$x3
000257330 9201_ $$0I:(DE-2719)1310007$$kAG Dityatev$$lMolecular Neuroplasticity$$x4
000257330 980__ $$ajournal
000257330 980__ $$aVDB
000257330 980__ $$aUNRESTRICTED
000257330 980__ $$aI:(DE-2719)1310005
000257330 980__ $$aI:(DE-2719)1310010
000257330 980__ $$aI:(DE-2719)5000006
000257330 980__ $$aI:(DE-2719)1310003
000257330 980__ $$aI:(DE-2719)1310007
000257330 9801_ $$aFullTexts